Breakthrough cancer therapy developed at Penn receives 2nd FDA approval

The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center. The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible fo r…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

Conclusions: LEO is a large and diverse cohort of newly diagnosed NHL patients and the first two years of enrollment reflects the broader United States NHL population. Enrollment is ongoing. This unique resource will enable examination of the interactions among a broad array of clinical and molecular factors and their impact on multiple outcomes, to improve prognostication, identify new approaches to improve outcomes and survivorship, and facilitate clinical trials using this infrastructure.DisclosuresFlowers: Acerta: Research Funding; Pharmacyclics/ Janssen: Consultancy; OptumRx: Consultancy; Janssen Pharmaceutical: Resea...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster I Source Type: research
The objective of this study was to explore whether changes in serum markers of inflammation underlie differences in cognitive functioning among patients treated for hematological malignancies.Methods. The sample comprised participants treated for lymphoma or multiple myeloma who were participating in a feasibility study of a computerized cognitive training program. Prior to the intervention, a battery of neuropsychological tests were administered to assess cognitive function in the following domains: Learning Efficiency and Memory; Information Processing and Psychomotor Efficiency; and Executive Functioning and Working Mem...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions Source Type: research
Conclusion We established that propagation of primary MCL in co-cultures with hMSCs depends on activation of FGF/FGFR-1 autocrine loop that enhances BIRC2/3 protein expression and thus, supports survival of MCL cells. We identified the factors essential for survival of MCL and MCL-ICs that present new targets for improved MCL treatment strategies. This study reveals that inhibition of FGFR-1 signaling by specific inhibitor has a profound positive impact on extrinsic cell death signaling; it enhances FAS sensitivity by promoting processing of caspases through enhanced BIRC2/3 degradation. The capacity of FGFR-1 inhibition t...
Source: Blood - Category: Hematology Authors: Tags: 622. Lymphoma Biology-Non-Genetic Studies: Poster II Source Type: research
In conclusion, these results provide new data validating HDACis and, especially, panobinostat as a novel anti-cancer therapy for veterinary applications, while contributing to comparative oncology. PMID: 29983882 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center. The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of certain adult patients with relapsed or refractory diffuse large B-cell lymphoma. The American Cancer …
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Till 1998, a little was known about alternative forms of regulated cell death beside apoptosis. In present scenario, accumulating evidences suggest a form of programmed necrosis called Necroptosis which can be induced by various external stimuli including anticancer drugs, ionizing radiation, photodynamic therapy in the form of death domain receptor (DR) engagement by their respective ligands, TNF-alpha, Fas ligand (FasL) and TRAIL, under apoptosis deficient condition (caspase inhibitor),etc. receptor interacting protein-1 (RIP-1), a death domain containing kinase is the key molecule in necroptotic cell death pathway. On i...
Source: Oncology Reviews - Category: Cancer & Oncology Source Type: research
Authors: Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L, Wang J, Li B Abstract IL-6 is critical for tumorigenesis. However, previous studies on the association of IL-6 promoter polymorphisms with predisposition to different cancer types are somewhat contradictory. Therefore, we performed this meta-analysis regarding the relationship between IL-6 promoter single nucleotide polymorphisms and cancer susceptibility and prognosis. Up to April 2017, 97 original publications were identified covering three IL-6 promoter SNPs. Our results showed statistically significant association between IL-6 promoter and cancer risk and pr...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
ConclusionWhile cancer therapies are known to increase the risk of CVD, this study additionally shows that CVD risk varies by sociodemographic factors.Implications for cancer survivorsThe identification and mitigation of CVD risk factors in these subgroups may improve long-term patient outcomes.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
Authors: Belay Y, Yirdaw K, Enawgaw B Abstract Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs in hematological malignant patients particularly non-Hodgkin's lymphoma and acute leukemia due to chemotherapy or spontaneously. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia and its clinical outcome is directly related to these biochemical abnormalities. Prevention and treatment of tumor lysis syndrome depend on immediate recognition of patients at risk. Therefore, identifying ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
CONCLUSION: Poor response against pneumococcal vaccines increases the susceptibility of respiratory diseases in these patients. In patients with NHL treated with RTX, the benefits achieved with IVIg replacement for the control of recurrent infectious diseases is of paramount importance. Clinicians dealing with monoclonal antibodies against cancer therapy, especially RTX, should be aware of the increasing risks for symptomatic induced hypogammaglobulinemia and respiratory infections. PMID: 29094629 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
More News: American Health | Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Health Management | Lymphoma | Non-Hodgkin's Lymphoma | University of Pennsylvania